The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

Inclusion Criteria

• men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
• good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)

Exclusion Criteria

• A vaccination in past two weeks
• Recent acute infection three weeks prior to enrollment
• Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
• Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
• Severe autoimmune disease requiring biological therapy
• Major severe illness and/or Hospitalization in past 3 months
• On warfarin or other medications that are considered a blood thinner
• Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test
• Known bleeding disorder
• Any conditions that would impair the function to perform grip strength test
• include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.
• Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)
• Baseline ECG QTc >450 ms in men and QTc >460 ms in women
• Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)